Skip to main content

Table 5 Comparison of the main adverse events and antithrombotic therapy according to the number of CMBs

From: The safety of antithrombotic therapy in patients with cerebral microbleeds and cardiogenic cerebral embolism due to nonvalvular atrial fibrillation

  Number of CMBs χ2 P value
≤5 n = 46 6–9 n = 24 ≥10 n = 40
Antithrombotic therapy
 Anticoagulant therapy (%) 18 (39.1) 8 (33.3) 28 (70.0) 11.208 0.004
 Antiplatelet therapy (%) 28 (60.9) 16 (66.7) 12 (30.0)   
CH events (%) 6 (13.0) 2 (8.3) 10 (25.0) 3.681 0.159
All-cause death (%) 8 (17.4) 2 (8.3) 4 (10.0) 1.586 0.453